首页> 美国卫生研究院文献>other >Micro and Nanoparticle Drug Delivery Systems for Preventing Allotransplant Rejection
【2h】

Micro and Nanoparticle Drug Delivery Systems for Preventing Allotransplant Rejection

机译:防止同种异体移植排斥的微米和纳米药物输送系统

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Despite decades of advances in transplant immunology, tissue damage caused by acute allograft rejection remains the primary cause of morbidity and mortality in the transplant recipient. Moreover, the long-term sequelae of lifelong immunosuppression leaves patients at risk for developing a host of other deleterious conditions. Controlled drug delivery using micro- and nanoparticles (MNPs) is an effective way to deliver higher local doses of a given drug to specific tissues and cells while mitigating systemic effects. Herein, we review several descriptions of MNP immunotherapies aimed at prolonging allograft survival. We also discuss developments in the field of biomimetic drug delivery that use MNP constructs to induce and recruit our bodies' own suppressive immune cells. Finally, we comment on the regulatory pathway associated with these drug delivery systems. Collectively, it is our hope the studies described in this review will help to usher in a new era of immunotherapy in organ transplantation.
机译:尽管数十年来移植免疫学取得了进步,但急性同种异体移植排斥引起的组织损伤仍然是移植受者发病和死亡的主要原因。此外,终生免疫抑制的长期后遗症使患者有发展其他许多有害疾病的风险。使用微米和纳米颗粒(MNP)进行受控的药物递送是一种将较高剂量的给定药物递送至特定组织和细胞,同时减轻系统性影响的有效方法。在本文中,我们回顾了旨在延长同种异体移植存活率的MNP免疫疗法的几种描述。我们还讨论了仿生药物递送领域的发展,该领域使用MNP构造来诱导和募集人体自身的抑制性免疫细胞。最后,我们评论与这些药物输送系统相关的调节途径。总的来说,我们希望本综述中描述的研究将有助于开创器官移植免疫疗法的新时代。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号